Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PSC Clear all
Completed No phase listed Observational

Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis

NCT02616705
View directory record Official record
Conditions
IgG4-related Sclerosing Cholangitis, IgG4-related Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Jul 22, 2026, 10:45 AM EDT
Recruiting No phase listed Observational

MRI Based Biomarkers in Pediatric Autoimmune Liver Disease

NCT03175471
View directory record Official record
Conditions
Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 23 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jul 22, 2026, 10:45 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

NCT04948203
View directory record Official record
Conditions
Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
Interventions
Sirolimus
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

RECOVER-SLEEP: Platform Protocol

NCT06404086
View directory record Official record
Conditions
Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
Interventions
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms

NCT05965726
View directory record Official record
Conditions
Long COVID-19, Long COVID
Interventions
Paxlovid, Ritonavir, Nirmatrelvir-matching placebo
Drug
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia

NCT00002912
View directory record Official record
Conditions
Leukemia
Interventions
etoposide, mitoxantrone hydrochloride, valspodar
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
50
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional

RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)

NCT06404060
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
Personalized Cardiopulmonary Rehabilitation, Education
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Not yet recruiting Phase 1 Interventional

Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

NCT07388550
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Keytruda
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 110 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated Phase 3 Interventional Results available

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

NCT03890120
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Cilofexor, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
82
States / cities
Glendale, Arizona • Phoenix, Arizona • Coronado, California + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis

NCT01085760
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Vancomycin, Metronidazole
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer

NCT00002826
View directory record Official record
Conditions
Breast Cancer
Interventions
paclitaxel, valspodar
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
9
States / cities
Palo Alto, California • Stanford, California • Flemington, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Jul 22, 2026, 10:45 AM EDT
Withdrawn Phase 2 Interventional

A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis

NCT06095986
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Aramchol meglumine
Drug
Lead sponsor
Galmed Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

NCT06920628
View directory record Official record
Conditions
Long COVID, Post Acute Sequelae of COVID-19
Interventions
11C-PS13
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

NCT01200082
View directory record Official record
Conditions
Hepatobiliary Diseases
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00004217
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, valspodar
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
56 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
89
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

NCT03561584
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Sulfasalazine, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
15 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

NCT05833217
View directory record Official record
Conditions
Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions
Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test
Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

RECOVER-AUTONOMIC Platform Protocol

NCT06305780
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care, Ivabradine Placebo + Coordinated Care, IVIG + Usual Care, IVIG Placebo + Usual Care, Ivabradine + Usual Care, Ivabradine Placebo + Usual Care
Drug
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
50
States / cities
Opelika, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2

NCT05040659
View directory record Official record
Conditions
Anosmia, Asymptomatic COVID-19, COVID-19 Respiratory Infection, Influenza, Healthy, PASC Post Acute Sequelae of COVID 19
Interventions
AROMHA Longitudinal Smell Test
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Active, not recruiting Not applicable Interventional

Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?

NCT05167227
View directory record Official record
Conditions
SARS-CoV-2 Acute Respiratory Disease, Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, Post-acute Sequelae of SARS-COV-2 Infection, Post COVID-19 Condition
Interventions
Extension for Community Healthcare Outcomes
Other
Lead sponsor
Family Health Centers of San Diego
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer

NCT00001570
View directory record Official record
Conditions
Kidney Neoplasms, Neoplasm Metastasis
Interventions
PSC 833, vinblastine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

NCT05946551
View directory record Official record
Conditions
COVID-19
Interventions
Cetirizine, Famotidine, Cetirizine Placebo, Famotidine Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Recruiting No phase listed Observational

Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health

NCT04573062
View directory record Official record
Conditions
Post-Coronavirus Disease 19
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
1,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

Amantadine Therapy for Cognitive Impairment in Long COVID

NCT06055244
View directory record Official record
Conditions
Long COVID, Post-COVID19 Condition, Post-Acute COVID19 Syndrome
Interventions
Amantadine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 22, 2026, 10:45 AM EDT